Improving how antibodies protect against infections
Increasing the protective capacity of antibodies by enhancing Fc-mediated responses
['FUNDING_R01'] · UNIVERSITY OF GEORGIA · NIH-11017221
This study is looking at ways to make vaccines and treatments work better by boosting the protective power of antibodies, especially for people whose antibodies don’t fight off infections as well as they should, so that everyone can have stronger defenses against germs.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-11017221 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the protective abilities of antibodies generated by vaccines and infections. It aims to understand how the Fc portion of antibodies can improve immune responses, particularly in cases where antibodies do not neutralize pathogens effectively. By investigating various factors that influence these Fc-mediated responses, the research seeks to develop better vaccines and antibody therapies that can provide stronger protection against a range of microbial infections. Patients may benefit from improved treatments that utilize both neutralizing and non-neutralizing antibodies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of infections that current vaccines do not adequately protect against.
Not a fit: Patients who have already developed strong immunity from existing vaccines or treatments may not see additional benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines and antibody therapies that provide better protection against infections.
How similar studies have performed: Previous research has shown promise in enhancing antibody responses through Fc-mediated mechanisms, indicating that this approach could lead to significant advancements.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BARB, ADAM WESLEY — UNIVERSITY OF GEORGIA
- Study coordinator: BARB, ADAM WESLEY
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.